文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

癌症免疫治疗时代临床无创T细胞追踪的前景与挑战

Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.
PubMed 文献 · EJNMMI Res · 2022-01-31

本综述概述了用于表征和研究抗癌免疫治疗诱导的T细胞反应的各种免疫影像工具,并讨论了将免疫影像工具用作预测性和替代性标志物以增强免疫治疗评估和成功应用时必须考虑和克服的挑战。

要点

  • 免疫治疗常伴随多种副作用及部分患者部分或完全无反应。
  • 纵向 interrogate 免疫细胞(尤其T细胞)全身迁移和扩增可能极大促进疾病表征与理解。
  • 免疫影像工具可作为预测性和替代性标志物,但需考虑并克服相关挑战。

核心结论

  • 免疫影像工具可用于表征和研究抗癌免疫治疗诱导的T细胞反应。
  • 将免疫影像工具用作预测性和替代性标志物前,必须考虑并克服相关挑战。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 已批准的免疫治疗方法主要基于免疫检查点抑制剂、抗体衍生的靶向治疗或细胞免疫治疗。
  • 这些疗法诱导或增强肿瘤反应性T细胞在肿瘤内的浸润和功能,理想情况下导致肿瘤完全根除。
  • 免疫治疗的临床应用显示出巨大前景,但常伴随多种副作用以及部分患者部分或完全无反应。
  • 不同疾病进展阶段引发不同的局部和全身免疫反应。
  • 纵向 interrogate 免疫细胞(尤其T细胞)全身迁移和扩增可能极大促进疾病表征与理解,并可作为指导开发及选择适当治疗方案的工​​具。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last decades, our understanding of the role of the immune system in cancer has significantly improved and led to the discovery of new immunotherapeutic targets and tools, which boosted the advances in cancer immunotherapy to fight a growing number of malignancies. Approved immunotherapeutic approaches are currently mainly based on immune checkpoint inhibitors, antibody-derived targeted therapies, or cell-based immunotherapies. In essence, these therapies induce or enhance the infiltration and function of tumor-reactive T cells within the tumors, ideally resulting in complete tumor eradication. While the clinical application of immunotherapies has shown great promise, these therapies are often accompanied either by a variety of side effects as well as partial or complete unresponsiveness of a number of patients. Since different stages of disease progression elicit different local and systemic immune responses, the ability to longitudinally interrogate the migration and expansion of immune cells, especially T cells, throughout the whole body might greatly facilitate disease characterization and understanding. Furthermore, it can serve as a tool to guide development as well as selection of appropriate treatment regiments. This review provides an overview about a variety of immune-imaging tools available to characterize and study T-cell responses induced by anti-cancer immunotherapy. Moreover, challenges are discussed that must be taken into account and overcome to use immune-imaging tools as predictive and surrogate markers to enhance assessment and successful application of immunotherapies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gosmann D, Russelli L, Weber WA, et al. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res. 2022. PMID: 35099641. doi:10.1186/s13550-022-00877-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。